GS, after looking at it again, I would tend to agree that the RECAF work is in the sale to GE. I was confused about what was included by "invitro diagnostics".
The CEO of Abbott was just on CNBC. He did say that GE was better suited to consolidate the automated systems diagnostics market. I take that to mean the Architect systems.
The Abbott site also mentions Immuno Diagnostics. It sounds like this would be part of the core business being sold and where our RECAF work may reside.
I think we will just have to wait and see to know for sure.
News 
Market Data 
Discover 
AI
